Dapagliflozin reduces all-cause & total hospitalisations in type 2 diabetes, including a separate statistically significant 14% reduction in infection-related hospitalisations - DECLARE data from Stephen Wiviott et al. thelancet.com/journals/landi…

#SGLT2i dapagliflozin now shown to reduce hospitalizations for any reason across cardio-renal-metabolic spectrum! Type 2 Diabetes #DECLARETIMI58: thelancet.com/journals/landi… Chronic Kidney Disease #DAPACKD: acpjournals.org/doi/10.7326/M2… Heart Failure #DELIVER: jacc.org/doi/epdf/10.10…

Terrific TIMI Study Group podcast with Marc Sabatine. One of the world's experts on lipid trials (among other things) discusses CLEAR Outcomes and #ACC2023. A quick and informative listen.

Congratulations Brian Bergmark. Doing great research with TIMI Study Group and a go to interventionalist for complex cases Brigham and Women's Hospital. Future is bright.

How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention ahajournals.org/doi/10.1161/CI… Glad to share these insights w/ Fatima Rodriguez on the FOURIER-OLE study TIMI Study Group Stephen Wiviott Josh Knowles Ann Marie Navar

Great to see so many Brigham and Women's Hospital class of 1996 Brigham and Women's Medicine Residents alumni. We haven’t changed a bit. #bwhreunion2023.

Do yourself a favor and listen to this terrific podcast with one of the true masters of cardiovascular clinical trials Robert Harrington and two rising stars David Berg and Nicholas Marston. Great lessons on leadership, learning & the past, present and future of clinical trials.

State Champions!

Primary results of the AZALEA-TIMI 71 Randomized Clinical Trial will be presented tomorrow by Dr. Christian Ruff in the Late-Breaking Science session at 8:15 AM in Main Event I Robert Giugliano Stephen Wiviott Sidhart Patel #AHA23

More from #SGLT2i DAPA-MI 🔸pts w. acute MI & impaired LV function, w/o prior DM, HF dapa demonstrated⬆️benefit w. regards to improvement of cardiometabolic outcomes vs placebo 🔸cardiometabolic benefit consistent among subgroups Dr Roxana Mehran Andrew J Sauer MD Marc Bonaca MD MPH Stephen Wiviott

Major (67-73%) reduction in bleeding with #abelacimab compared to rivaroxiban with this novel Factor XI inhibitor, including near elimination of GI bleeding. #AHA23

Our science only works as a team effort. These impactful papers are a credit to the whole TIMI Study Group - faculty, fellows, operations, statistics and so many more.

Congratulations to our newest Cardiology fellows joining the Brigham Fellows in the coming year!! We are so excited to welcome you to Brigham Heart!!! 🥳🥳🫀🫀

Another great podcast - this time with amazing colleague Michelle O'Donoghue. Always a lot to learn from her. This time about Lp(a) - a very hot area in prevention - even the 2 acceptable ways to say “Lp(a)!”

⁦⁦Brigham and Women’s Research⁩ , ⁦Mass General Research Institute⁩ are the top 2 hospitals world-wide in research impact according to Nature. What a privilege to support and be a part of research ⁦Mass General Brigham⁩. nature.com/nature-index/n…